1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for pancreatic adenocarcinoma , https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
Google Scholar2. Seufferlein, T, Hammel, P, Delpero, JR, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev 2019; 77: 1–10.
Google Scholar | Crossref | Medline3. Picozzi, V, Alseidi, A, Winter, J, et al. Gemcitibine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open 2020; 5: e000668.
Google Scholar | Crossref | Medline4. Chatzizacharias, NA, Tsai, S, Griffin, M, et al. Locally advanced pancreas cancer: staging and goals of therapy. Surgery 2018; 163: 1053–1062.
Google Scholar | Crossref | Medline5. Shah, R, Ostapoff, KT, Kuvshinoff, B, et al. Ablative therapies for locally advanced pancreatic cancer. Pancreas 2018; 47: 6–11.
Google Scholar | Crossref | Medline6. Brody, T . Endpoint of event free survival. Clinical trials: Study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines. Amsterdam: Academic Press, Elsevier, 2016.
Google Scholar7. Kantarjian, H, O’Brien, S, Jabbour, E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 2011; 29: 3173–3178.
Google Scholar | Crossref | Medline8. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/efs
Google Scholar9. Mathoulin-Pelissier, S, Gourgou-Bourgade, S, Bonnetain, F, et al. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 2008; 26: 3721–3726.
Google Scholar | Crossref | Medline | ISI10. Bonnetain, F, Bonsing, B, Conroy, T, et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Eur J Cancer 2014; 50: 2983–2993.
Google Scholar | Crossref | Medline11. Othus, M, van Putten, W, Lowenberg, B, et al. Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI. Haematologica 2016; 101: e284–e286.
Google Scholar | Crossref | Medline12. Wudhikarn, K, Bunworasate, U, Julamanee, J, et al. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. Thai Lymphoma Study Group. Hematol Oncol 2019; 37: 578–585.
Google Scholar | Crossref | Medline13. Doganis, D, Zborovskaya, A, Trojanowski, M, et al. Wilms tumour event-free and overall survival in Southern and Eastern Europe: pooled analysis of clinical data from four childhood cancer registries (1999-2017). Eur J Cancer 2019; 115: 37–46.
Google Scholar | Crossref | Medline14. Creutzig, U, Zimmermann, M, Lehrnbecher, T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499–4506.
Google Scholar | Crossref | Medline15. Langebrake, C, Creutzig, U, Dworzak, M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006; 24: 3686–3692.
Google Scholar | Crossref | Medline16. Marcucci, G, Maharry, K, Whitman, SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007; 25: 3337–3343.
Google Scholar | Crossref | Medline17. Rao, AV, Valk, PJ, Metzeler, KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 5580–5586.
Google Scholar | Crossref | Medline18. Basso, G, Veltroni, M, Valsecchi, MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27: 5168–5174.
Google Scholar | Crossref | Medline19. Butturini, AM, Dorey, FJ, Lange, BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007; 25: 2063–2069.
Google Scholar | Crossref | Medline20. Nachman, JB, La, MK, Hunger, SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children’s oncology group. J Clin Oncol 2009; 27: 5189–5194.
Google Scholar | Crossref | Medline | ISI21. Schultz, KR, Bowman, WP, Aledo, A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 2009; 27: 5175–5181.
Google Scholar | Crossref | Medline | ISI22. Cortes, JE, Jones, D, O’Brien, S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28: 398–404.
Google Scholar | Crossref | Medline | ISI23. Caballero, D, García-Marco, JA, Martino, R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 2005; 11: 7757–7763.
Google Scholar | Crossref | Medline | ISI24. Adès, L, Chevret, S, Raffoux, E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703–5710.
Google Scholar | Crossref | Medline | ISI25. Devine, S, Dagher, RN, Weiss, KD, et al. Good clinical practice and the conduct of clinical studies in pediatric oncology. Pediatr Clin North Am 2008; 55: 187–209.
Google Scholar | Crossref | Medline26. Fleming, TR, Harrington, DP. Counting processes and survival analysis. Chichester: Wiley, 1991.
Google Scholar27. Pietrasz, D, Turrini, O, Vendrely, V, et al. How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort. Ann Surg Oncol 2019; 26: 109–117.
Google Scholar | Crossref | Medline28. Kunzmann, V, Algül, H, Goekkurt, E, et al. Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitibine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): final results of a multicenter randomised phase II AIO trial. Ann Oncol 2019; 30: v253–v324.
Google Scholar | Crossref29. Huguet, F, Goodman, KA, Azria, D, et al. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int J Radiat Oncol Biol Phys 2012; 83: 1355–1364.
Google Scholar | Crossref | Medline30. Reni, M, Zanon, S, Balzano, G, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol 2017; 28: 2786–2792.
Google Scholar | Crossref | Medline31. Philip, AP, Lacy, J, Portales, F, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 2020; 5: 285–294.
Google Scholar | Crossref | Medline32. Suker, M, Beumer, BR, Sadot, E, et al. A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer. Lancet Oncol 2016; 17: 801–810.
Google Scholar | Crossref | Medline | ISI